Aojiahua announced abnormal stock trading fluctuations. The company's stock rose and stopped for four consecutive trading days from September 21 to September 24, 2026, with a cumulative increase of about 46.65%. Among them, the deviation value of the closing price increase for two consecutive trading days exceeded 20%. According to verification, the company's wholly-owned subsidiary is still in the early stages of exploring the application of health service robots. It has not yet involved the field of humanoid robots and has not generated sales revenue; some health care products are used in pension scenarios, and the revenue share is not high; some export business involves RCEP member countries, with limited benefits; and its main business is not carried out within the Xiamen Free Trade Zone. In addition, the company's shareholders intend to agree to transfer 62.373,900 shares. This matter still needs to be reviewed. There is uncertainty, and it will not lead to changes in the controlling shareholders and actual controllers of the company. The company's production and operation are normal, and there are no important matters that should be disclosed but not disclosed. According to financial data, in the first half of 2026, the company achieved operating income of 2,703 billion yuan, a year-on-year increase of 16.14%; net profit to mother of 73.924 million yuan, a year-on-year decrease of 373.47%; deducted non-net profit of 91.5419 million yuan, a year-on-year decrease of 653.35%. The company's latest rolling price-earnings ratio is negative, which is quite different from the same industry.

Aojiahua announced abnormal stock trading fluctuations. The company's stock rose and stopped for four consecutive trading days from September 21 to September 24, 2026, with a cumulative increase of about 46.65%. Among them, the deviation value of the closing price increase for two consecutive trading days exceeded 20%. According to verification, the company's wholly-owned subsidiary is still in the early stages of exploring the application of health service robots. It has not yet involved the field of humanoid robots and has not generated sales revenue; some health care products are used in pension scenarios, and the revenue share is not high; some export business involves RCEP member countries, with limited benefits; and its main business is not carried out within the Xiamen Free Trade Zone. In addition, the company's shareholders intend to agree to transfer 62.373,900 shares. This matter still needs to be reviewed. There is uncertainty, and it will not lead to changes in the controlling shareholders and actual controllers of the company. The company's production and operation are normal, and there are no important matters that should be disclosed but not disclosed. According to financial data, in the first half of 2026, the company achieved operating income of 2,703 billion yuan, a year-on-year increase of 16.14%; net profit to mother of 73.924 million yuan, a year-on-year decrease of 373.47%; deducted non-net profit of 91.5419 million yuan, a year-on-year decrease of 653.35%. The company's latest rolling price-earnings ratio is negative, which is quite different from the same industry.